Vivoryon Therapeutics NV (FRA:05Y)

€ 1.964 0.062 (3.26%) Market Cap: 52.03 Mil Enterprise Value: 36.69 Mil PE Ratio: 0 PB Ratio: 3.79 GF Score: 34/100

Half Year 2024 Vivoryon Therapeutics NV Earnings Call Transcript
Sep 12, 2024

€2.1 (+10.18%)

Earnings
Q1 2024 Vivoryon Therapeutics NV Earnings Call Transcript
May 23, 2024

€1.26 (+62.37%)

Earnings
Q4 2023 Vivoryon Therapeutics NV Earnings Call Transcript
Apr 24, 2024

€0.83 (+11.41%)

Earnings
Q3 2023 Vivoryon Therapeutics NV Earnings Call Transcript
Dec 06, 2023

€7.48 (-0.13%)

Earnings
Vivoryon Therapeutics NV at Virtual R&D Event with Key Opinion Leaders Transcript
Oct 17, 2023
Half Year 2023 Vivoryon Therapeutics NV Earnings Call Transcript
Sep 07, 2023

€12 (-1.80%)

Earnings
Q4 2022 Vivoryon Therapeutics NV Earnings Call Transcript
Apr 19, 2023

€12.98 (-7.15%)

Earnings
Vivoryon Therapeutics NV at Barclays Global Healthcare Conference Transcript
Mar 16, 2023
Q3 2022 Vivoryon Therapeutics NV Earnings Call Transcript
Nov 22, 2022

€9.03 (-9.88%)

Earnings
Q2 2022 Vivoryon Therapeutics NV Earnings Call Transcript
Sep 30, 2022

Earnings
Vivoryon Therapeutics NV Corporate Call Transcript
Aug 02, 2022
Vivoryon Therapeutics NV Annual Shareholders Meeting Transcript
Jun 22, 2022
Q4 2021 Vivoryon Therapeutics NV Earnings Call Transcript
Apr 28, 2022

€8.8 (+1.85%)

Earnings
Q2 2021 Vivoryon Therapeutics NV Earnings Call Transcript
Sep 21, 2021

€18.16 (-0.22%)

Earnings

Half Year 2024 Vivoryon Therapeutics NV Earnings Call Transcript

Sep 12, 2024 / 01:00PM GMT

Release Date Price: €2.1 (+10.18%)

Transcript

Operator

Good day, and thank you for standing by. Welcome to the Vivoryon Therapeutics 2024 Half Year Results Conference Call and Webcast. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to turn the conference over to your speaker, Anne Doering. Please go ahead.

Anne Doering

Vivoryon Therapeutics NV - Chief Strategy & Investor Relations Officer

Thank you, Ralph. Good afternoon, and thank you for joining us today to discuss the company's first half 2024 results and operational updates. This morning, Vivoryon issued a press release reporting its first half 2024 financial results and also provided an update on our progress, which was marked by compelling kidney function data as well as execution of important steps in implementing our strategy to advance varoglutamstat in kidney disease. This press release is posted on Vivoryon's website at www.vivoryon.com.

On the call with me today are Vivoryon's Chief Executive Officer, Frank

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.